Capricor soars on potential FDA review extension, filing amendments

RegulatoryderamiocelPositive

AI Analysis

Summary

Capricor Therapeutics' stock surged 68% on CEO commentary suggesting the FDA may extend its review timeline for deramiocel, a Duchenne muscular dystrophy cell therapy, ahead of the August 22 deadline.

Outcome Details

Potential FDA review extension

Importance:6/10

Sentiment:

0.65

FDAcell therapyDuchenne muscular dystrophyregulatorystock movement

Related Companies

$CAPR

Read the original article

Published by BioSpace on August 14, 2026 3:32 PM

Read Original